Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial
PaperCitations, authors & open-access status
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 69 citations, 2022 year and hybrid oa status.
69
Citations
2022
Year
hybrid
OA Status